Investigation of the relationship between IL17A, IL17F and ILR1N polymorphisms and COVID‐19 severity: The predictive role of IL17A rs2275913 polymorphism in the clinical course of COVID‐19

Coronavirus disease 2019 (COVID‐19) is an infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Although the mortality rate of the disease has been relatively under control as of 2022, more than 15 million confirmed COVID‐19 cases have been detected in Turkey to date, causing more than 100,000 deaths. The clinical manifestation of the disease varies widely, ranging from asymptomatic to acute respiratory distress syndrome causing death. The immune response mechanisms have an important impact on the fine adjustment between healing and enhanced tissue damage. This study aims to investigate the relationship between the variants of the interleukin 1 receptor antagonist (IL1RN), interleukin 17A (IL17A), and interleukin 17F (IL17F) genes and COVID‐19 severity. The study population comprised 202 confirmed COVID‐19 cases divided into three groups according to severity. The IL1RN variable number of a tandem repeat (VNTR) polymorphism was genotyped by polymerase chain reaction (PCR), and IL17A rs2275913, IL17F rs763780 and rs2397084 polymorphisms were genotyped by the PCR‐based restriction fragment length polymorphism method. Statistical analysis revealed a significant association between IL17A rs2275913 variant and COVID‐19 severity. The AA genotype and the A allele of IL17A rs2275913 were found significant in the severe group. Additionally, we found a significant relationship between haplotype frequency distributions and severity of COVID‐19 for the IL17F rs763780/rs2397084 (p = 0.044) and a combination of IL17F rs763780/rs2397084/ IL17A rs2275913 (p = 0.04). The CG and CGA haplotype frequencies were significantly higher in the severe group. IL17A rs2275913, IL17F rs763780 and rs2397084 variants appear to have important effects on the immune response in COVID‐19. In conclusion, variants of IL17A rs2275913, IL17F rs763780 and rs2397084 may be the predictive markers for the clinical course and potential immunomodulatory treatment options in COVID‐19, a disease that has placed a significant burden on our country.

[1]  R. Ahmed,et al.  IL-17A )rs2275913; G197A) gene polymorphism as predictor for disease severity and its correlation with IL-17 serum levels in COVID-19 patients. , 2022, Egyptian Journal of Immunology.

[2]  S. Sargazi,et al.  Single nucleotide polymorphisms located in TNFA, IL1RN, IL6R, and IL6 genes are associated with COVID‐19 risk and severity in an Iranian population , 2022, Cell biology international.

[3]  R. Saravani,et al.  Association of TMPRSS2 Gene Polymorphisms with COVID-19 Severity and Mortality: a Case-Control Study with Computational Analyses , 2022, Applied Biochemistry and Biotechnology.

[4]  K. Tokunaga,et al.  Genetic association of IL17 and the importance of ABO blood group antigens in saliva to COVID-19 , 2022, Scientific Reports.

[5]  R. Saravani,et al.  Association of polymorphisms in tumor necrosis factors with SARS‐CoV‐2 infection and mortality rate: A case‐control study and in silico analyses , 2021, Journal of medical virology.

[6]  W. El-Deiry,et al.  Cytokine ranking via mutual information algorithm correlates cytokine profiles with presenting disease severity in patients infected with SARS-CoV-2 , 2021, eLife.

[7]  N. Alajez,et al.  Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19 , 2020, Cells.

[8]  Purva Asrani,et al.  SARS-CoV-2 mediated lung inflammatory responses in host: targeting the cytokine storm for therapeutic interventions , 2020, Molecular and Cellular Biochemistry.

[9]  G. Mosayebi,et al.  Cytokine profile and disease severity in patients with COVID-19 , 2020, Cytokine.

[10]  M. Wurfel,et al.  A Case for Targeting Th17 Cells and IL-17A in SARS-CoV-2 Infections , 2020, The Journal of Immunology.

[11]  J. Knight,et al.  Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease. , 2020, JCI insight.

[12]  H. Maecker,et al.  Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis , 2020, medRxiv.

[13]  S. Evans,et al.  COVID-19: a case for inhibiting IL-17? , 2020, Nature Reviews Immunology.

[14]  Stefano Volpi,et al.  On the Alert for Cytokine Storm: Immunopathology in COVID‐19 , 2020, Arthritis & rheumatology.

[15]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[16]  Dandan Wu,et al.  TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib , 2020, Journal of Microbiology, Immunology and Infection.

[17]  Lei Liu,et al.  Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury , 2020, National science review.

[18]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[19]  P. Mehrbod,et al.  Association of polymorphisms in inflammatory cytokines encoding genes with severe cases of influenza A/H1N1 and B in an Iranian population , 2019, Virology Journal.

[20]  Ping Chen,et al.  Association of Interleukin-17F 7488A/G and 7383A/G Polymorphisms With Rheumatoid Arthritis: A Meta-Analysis. , 2019, Archives of rheumatology.

[21]  Teng Ma,et al.  The association between IL‐17A and IL‐23R polymorphisms and coronary artery disease risk in a Middle Eastern Chinese population , 2019, Journal of clinical laboratory analysis.

[22]  K. Safranow,et al.  IL17A and IL17F genes polymorphisms are associated with histopathological changes in transplanted kidney , 2019, BMC Nephrology.

[23]  Lidong Wu,et al.  Association between interleukin-17A/F single nucleotide polymorphisms and susceptibility to osteoarthritis in a Chinese population , 2019, Medicine.

[24]  K. Khazim,et al.  Interleukin 1 gene polymorphism and susceptibility to disease , 2018, Immunological Reviews.

[25]  E. Eskandari-Nasab,et al.  Interleukin-17 A and F gene polymorphisms affect the risk of tuberculosis: An updated meta-analysis. , 2017, The Indian journal of tuberculosis.

[26]  S. Batra,et al.  Immune-related gene polymorphisms in pulmonary diseases. , 2017, Toxicology.

[27]  S. Bae,et al.  Associations between circulating IL-17 levels and rheumatoid arthritis and between IL-17 gene polymorphisms and disease susceptibility: a meta-analysis , 2017, Postgraduate Medical Journal.

[28]  E. Eskandari-Nasab,et al.  Meta-Analysis of Risk Association Between Interleukin-17A and F Gene Polymorphisms and Inflammatory Diseases. , 2017, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[29]  M. Yekaninejad,et al.  Seasonal influenza A/H3N2 virus infection and IL‐1Β, IL‐10, IL‐17, and IL‐28 polymorphisms in Iranian population , 2016, Journal of medical virology.

[30]  F. Polack,et al.  IL-8/IL-17 gene variations and the susceptibility to severe viral bronchiolitis , 2016, Epidemiology and Infection.

[31]  K. Safranow,et al.  IL17A and IL17F gene polymorphisms in patients with rheumatoid arthritis , 2016, BMC Musculoskeletal Disorders.

[32]  T. Ren,et al.  Blockade of Interleukin‐17 Restrains the Development of Acute Lung Injury , 2016, Scandinavian journal of immunology.

[33]  Ming Li,et al.  Association Analysis of Interleukin-17 Gene Polymorphisms with the Risk Susceptibility to Tuberculosis , 2016, Lung.

[34]  M. Karimi,et al.  Association of IL-17, IL-21, and IL-23R gene polymorphisms with HBV infection in kidney transplant patients. , 2013, Viral immunology.

[35]  Ying Wang,et al.  Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population , 2013, Inflammation Research.

[36]  R. G. Resende,et al.  Association between Polymorphisms in Interleukin-17A and -17F Genes and Chronic Periodontal Disease , 2012, Mediators of inflammation.

[37]  E. Liu,et al.  The Polymorphism of IL-17 G-152A was Associated with Childhood Asthma and Bacterial Colonization of the Hypopharynx in Bronchiolitis , 2010, Journal of Clinical Immunology.

[38]  T. Merriman,et al.  Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand. , 2009, Rheumatology.

[39]  Xiang Gao,et al.  Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population , 2009, Scandinavian journal of gastroenterology.

[40]  Y. Nojima,et al.  The Influence of Polymorphisms of Interleukin-17F Genes on the Susceptibility and Clinical Significanse of Chronic Idiopathic Thrombocytopenic Purpura. , 2008 .

[41]  T. Tahara,et al.  The Influence of Polymorphisms of Interleukin-17A and Interleukin-17F Genes on the Susceptibility to Ulcerative Colitis , 2007, Journal of Clinical Immunology.

[42]  M. Kawaguchi,et al.  Role of interleukin‐17F in chronic inflammatory and allergic lung disease , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[43]  G. Ferraccioli,et al.  IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. , 2006, Pharmacogenomics.

[44]  K. Vandenbroeck.  Cytokine Gene Polymorphisms in Multifactorial Conditions , 2006 .

[45]  J. Edmonds,et al.  Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). , 2006, Arthritis and rheumatism.

[46]  M. Nishimura,et al.  IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. , 2006, The Journal of allergy and clinical immunology.

[47]  S. Gaffen,et al.  Crucial Role for Nuclear Factor of Activated T Cells in T Cell Receptor-mediated Regulation of Human Interleukin-17* , 2004, Journal of Biological Chemistry.

[48]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[49]  A. Blakemore,et al.  Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat , 1993, Human Genetics.

[50]  R. Bone,et al.  Immunologic Dissonance: A Continuing Evolution in Our Understanding of the Systemic Inflammatory Response Syndrome (SIRS) and the Multiple Organ Dysfunction Syndrome (MODS) , 1996, Annals of Internal Medicine.

[51]  D. Patterson,et al.  The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. , 1993, Genomics.

[52]  T. Krakauer.  Human interleukin 1. , 1986, Critical reviews in immunology.